- Home
- ABTC vs ABEO Comparison
ABTC vs ABEO Comparison
Compare ABTC & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABTC | ABEO |
|---|---|---|
| Founded | 2024 | 1974 |
| Country | United States | United States |
| Employees | 59 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 445.3M | 399.5M |
| IPO Year | 2020 | 2005 |
Fundamental Metrics
Financial Performance| Metric | ABTC | ABEO |
|---|---|---|
| Price | $8.50 | $6.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $4.00 | ★ $20.00 |
| AVG Volume (30 Days) | 1.5M | ★ 1.6M |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 66.67 | ★ 165.16 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $185,164,000.00 | $2,998,000.00 |
| Revenue This Year | $79.69 | $1,024.31 |
| Revenue Next Year | $50.64 | $145.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 801.52 | 258.18 |
| 52 Week Low | $0.56 | $4.00 |
| 52 Week High | $10.24 | $7.65 |
Technical Indicators
Market Signals| Indicator | ABTC | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 68.65 | 42.92 |
| Support Level | $4.98 | $5.68 |
| Resistance Level | $9.33 | $7.51 |
| Average True Range (ATR) | 0.63 | 0.31 |
| MACD | 0.06 | -0.11 |
| Stochastic Oscillator | 83.51 | 19.23 |
Price Performance
Historical ComparisonAbout ABTC American Bitcoin Corp.
American Bitcoin Corp is a Bitcoin accumulation platform that integrates scaled Bitcoin mining operations with disciplined accumulation strategies. Its business is engaged in the operation of application-specific integrated circuit ("ASIC") miners for mining Bitcoin and the strategic accumulation of a Bitcoin reserve.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.